Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Teva Pharmaceutical Industries Ltd. TEVA

Healthcare  —  Drug Manufacturers Specialty & Generic
39.19 (1.03) (2.56%) as of 25 Sep
Market cap
$46.9B
P/E
62.2×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Teva Pharmaceutical Industries Ltd. (TEVA) Business Profile

Updated before January 2025

Company Overview

Teva Pharmaceutical Industries Ltd. (TEVA) is a global leader in the pharmaceutical industry, specializing in the development, production, and marketing of generic and specialty medicines. Founded in 1901 in Jerusalem, the company has grown from a small wholesale drug business into one of the largest pharmaceutical companies in the world. Teva is headquartered in Petah Tikva, Israel, and operates in over 60 countries, employing more than 35,000 people globally.

Teva’s leadership team is composed of experienced professionals who drive the company’s strategic vision. As of 2023, Richard Francis serves as the President and Chief Executive Officer (CEO), bringing extensive experience in the pharmaceutical and biotechnology sectors. The company’s board of directors and executive management team are committed to innovation, operational excellence, and delivering high-quality healthcare solutions to patients worldwide.

Core Business Segments

Teva operates through two primary business segments: Generic Medicines and Specialty Medicines. These segments encompass a wide range of products and services designed to meet diverse healthcare needs.

Generic Medicines

Teva is one of the largest manufacturers of generic medicines globally, offering affordable alternatives to branded drugs. The company’s generic portfolio includes treatments across various therapeutic areas such as cardiovascular, central nervous system (CNS), respiratory, and oncology. Key products in this segment include:

  • Generic versions of branded drugs: Teva produces high-quality generics for widely used medications, ensuring accessibility and affordability for patients.
  • Over-the-counter (OTC) products: Teva offers a range of OTC medications, including pain relievers, cold and flu remedies, and allergy treatments.

Specialty Medicines

Teva’s specialty medicines segment focuses on innovative treatments for complex and chronic conditions. This segment includes:

  • CNS Treatments: Products like Copaxone® for multiple sclerosis and Ajovy® for migraine prevention.
  • Respiratory Products: ProAir® and Qvar® for asthma and chronic obstructive pulmonary disease (COPD).
  • Biologics and Biosimilars: Teva is expanding its portfolio of biologics and biosimilars to address unmet medical needs.

Business Model

Teva’s business model is centered on providing high-quality, cost-effective healthcare solutions. The company integrates its generic and specialty medicine offerings to create a comprehensive portfolio that addresses a wide range of medical needs. Revenue generation is driven by:

  1. Generic Medicines: Teva leverages its extensive manufacturing capabilities and global distribution network to produce and supply generic drugs at scale.
  2. Specialty Medicines: The company invests heavily in research and development (R&D) to bring innovative therapies to market.
  3. Partnerships and Collaborations: Teva collaborates with other pharmaceutical companies, research institutions, and healthcare providers to enhance its product offerings and expand its market reach.

Strategic Direction

Teva is focused on achieving sustainable growth through innovation, operational efficiency, and strategic investments. Key elements of the company’s strategic direction include:

  • Pipeline Expansion: Teva is investing in R&D to develop new specialty medicines, biosimilars, and innovative therapies.
  • Digital Transformation: The company is leveraging digital technologies to improve patient outcomes and streamline operations.
  • Sustainability Goals: Teva is committed to reducing its environmental footprint, with initiatives aimed at minimizing waste, conserving energy, and promoting sustainable practices across its operations.
  • Geographic Expansion: Teva is exploring opportunities to expand its presence in emerging markets, where demand for affordable healthcare solutions is growing.

Competitive Landscape

Teva operates in a highly competitive industry, facing competition from both generic and branded pharmaceutical companies. Key competitors include:

  • Generic Pharmaceuticals: Companies like Sandoz (a division of Novartis), Mylan (now part of Viatris), and Sun Pharma.
  • Specialty Pharmaceuticals: Competitors such as Biogen, Amgen, and Eli Lilly in the CNS and biologics segments.
  • Biosimilars: Rivals like Pfizer and Samsung Bioepis in the biosimilars market.

Teva differentiates itself through its extensive product portfolio, global manufacturing capabilities, and commitment to innovation.

Risk Factors

Teva faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The pharmaceutical industry is heavily regulated, and changes in regulations or compliance issues could affect Teva’s operations.
  • Market Dependence: A significant portion of Teva’s revenue comes from a few key products, making the company vulnerable to market fluctuations and competition.
  • Supply Chain Disruptions: Global supply chain issues, including raw material shortages and transportation challenges, could impact production and distribution.
  • Litigation and Legal Risks: Teva is involved in various legal proceedings, including patent disputes and opioid-related lawsuits, which could result in financial liabilities.

Recent Developments

Teva has made significant strides in recent years, including:

  • New Product Launches: The introduction of biosimilars and innovative therapies, such as Ajovy® for migraine prevention.
  • Strategic Partnerships: Collaborations with biotech companies to develop and commercialize new treatments.
  • Operational Improvements: Initiatives to optimize manufacturing processes and reduce costs.
  • Global Developments: The COVID-19 pandemic highlighted the importance of Teva’s role in ensuring the availability of essential medicines worldwide.

Investment Considerations

Investors considering Teva should weigh the company’s strengths and risks:

Strengths

  • Market Leadership: Teva is a global leader in generic medicines, with a strong presence in key markets.
  • Diverse Portfolio: The company’s broad product range reduces dependence on any single product or market.
  • Innovation: Teva’s focus on R&D and pipeline expansion positions it for long-term growth.

Risks

  • Legal and Regulatory Issues: Ongoing litigation and regulatory challenges could impact financial performance.
  • Market Competition: Intense competition in both generic and specialty segments may pressure margins.
  • Debt Levels: Teva’s high debt levels could limit its ability to invest in growth opportunities.

Conclusion

Teva Pharmaceutical Industries Ltd. is a global leader in the pharmaceutical industry, offering a diverse portfolio of generic and specialty medicines. The company’s commitment to innovation, operational excellence, and sustainability positions it for long-term success. While challenges such as regulatory risks and market competition remain, Teva’s strategic initiatives and strong market presence make it a compelling player in the healthcare sector. Looking ahead, the company is well-positioned to capitalize on emerging opportunities and drive sustainable growth.